← Leaderboards
Sergei V Kotenko
Rutgers Biomedical And Health Sciences
$7,576,497
Attributed
$11,498,398
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,498,398 · 5
By mechanism
R01$11,069,398 · 4
R21$429,000 · 1
Top collaborators
- Joan E. Durbin6 shared
- Raymond B Birge4 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Raymond B Birge$4,162,311
- Pingping Hou$2,730,524
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsReceptorSignal TransductionGenesCellsBiologyAntiviral AgentsInterferonsComplexVirusBiologicalVirus DiseasesViralReceptor ExpressionPreventTissuesImmuneIn VivoFamilyPathogenesisLife Cycle StagesLifeInterferon-AlphaImmune System
Grant awards (22)
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$473,506
R01 · FY2025 · CA
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$453,632
R01 · FY2024 · CA
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$473,620
R01 · FY2023 · CA
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer$508,157
R01 · FY2022 · CA
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,190,331
R01 · FY2017 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,185,932
R01 · FY2016 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,185,932
R01 · FY2015 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,185,617
R01 · FY2014 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,036,895
R01 · FY2013 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$150,180
R01 · FY2013 · AI · contact PI
Evasion of antiviral protection by poxvirus-encoded interferon antagonists$234,000
R21 · FY2010 · AI · contact PI
Role of Interferon-lambda in Antiviral Response$361,601
R01 · FY2009 · AI · contact PI
Evasion of antiviral protection by poxvirus-encoded interferon antagonists$195,000
R21 · FY2009 · AI · contact PI
Role of Interferon-lambda in Antiviral Response$361,601
R01 · FY2008 · AI · contact PI
Role of Interferon-lambda in Antiviral Response$368,605
R01 · FY2007 · AI · contact PI
Role of Interferon-lambda in Antiviral Response$379,614
R01 · FY2006 · AI · contact PI
Role of Interferon-lambda in Antiviral Response$380,425
R01 · FY2005 · AI
Characterization of the IL-TIF Receptor Complex$274,750
R01 · FY2005 · AI
Characterization of the IL-TIF Receptor Complex$274,750
R01 · FY2004 · AI
Characterization of the IL-TIF Receptor Complex$274,750
R01 · FY2003 · AI
Characterization of the IL-TIF Receptor Complex$274,750
R01 · FY2002 · AI
Characterization of the IL-TIF Receptor Complex$274,750
R01 · FY2001 · AI